Modulation of il-2- and il-15-mediated t cell responses
CA 2422294 C · Owner: Li, Xian Chang · Inventors: Li, Xian Chang; Strom, Terry B.; Zheng, Xin Xiao
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention is based, in part on expression studies of IL-2 and IL-, 15 receptor subunits by cycling T cells in vivo. In one embodiment the , invention generally features novel combinations of IL-2 and IL-15 antagonists and methods of suppressing the immune response by administering these antagonists. In each case, suppression is achieved by administration of a first agent that targets an IL-15 molecule or an IL-15 receptor (IL-15R) and a second agent that targets an IL-2 molecule or an IL-2 receptor (IL-2R). More generally, the invention features novel combinations of agents that when , administered to a patient (or to a transplant ex vivo reduce the number of , …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 14, 2001 and granted December 4, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended September 14, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 14, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.